LONG-TERM COST-EFFECTIVENESS OF IGLARLIXI VERSUS IDEGLIRA IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES TREATED WITH BASAL INSULIN OR ORAL ANTIDIABETIC DRUG IN CHINA

被引：0
|
作者：
Mo, X. [1 ]
Ai, Y. [2 ]
Tan, J. [3 ]
Wang, L. J. [3 ]
机构：
[1] IQVIA China, Real World Solut, Shanghai 31, Peoples R China
[2] IQVIA China, Real World Solut, Shanghai, Peoples R China
[3] Sanofi, Shanghai, Peoples R China
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE107
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [41] Evaluating the long-term cost-effectiveness of insulin aspart (novorapid®) versus human soluble insulin in patients with type 2 diabetes in Spain and Italy
    Erny-Albrecht, W.
    Goodall, G.
    Townsend, C.
    Kotchie, R.
    Nielsen, S.
    Valentine, W. J.
    VALUE IN HEALTH, 2007, 10 (06) : A260 - A260
  • [42] IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting
    Barnaby Hunt
    Michelle Mocarski
    William J. Valentine
    Jakob Langer
    Diabetes Therapy, 2017, 8 : 531 - 544
  • [43] The efficacy of long-term insulin glargine and oral antidiabetic therapy in patients with type 2 diabetes
    Schreiber, S
    Schneider, K
    Schweitzer, MA
    DIABETES, 2005, 54 : A143 - A143
  • [44] IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting
    Hunt, Barnaby
    Mocarski, Michelle
    Valentine, William J.
    Langer, Jakob
    DIABETES THERAPY, 2017, 8 (03) : 531 - 544
  • [45] Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK
    Rory J. McCrimmon
    Edel Falla
    Jo Zhou Sha
    Abdul Jabbar Omar Alsaleh
    Elisheva Lew
    Richard Hudson
    Mike Baxter
    Karen Palmer
    Diabetes Therapy, 2021, 12 : 3217 - 3230
  • [46] Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK
    McCrimmon, Rory J.
    Falla, Edel
    Sha, Jo Zhou
    Alsaleh, Abdul Jabbar Omar
    Lew, Elisheva
    Hudson, Richard
    Baxter, Mike
    Palmer, Karen
    DIABETES THERAPY, 2021, 12 (12) : 3217 - 3230
  • [47] Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic
    Kvapil, Milan
    Prazny, Martin
    Holik, Pavel
    Rychna, Karel
    Hunt, Barnaby
    DIABETES THERAPY, 2017, 8 (06) : 1331 - 1347
  • [48] EVALUATING SHORT-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS ORAL ANTIDIABETIC DRUGS IN PATIENTS WITH TYPE 2 DIABETES IN A CHINESE SETTING
    Shi, L. W.
    Han, S.
    Sun, F.
    Liu, F.
    VALUE IN HEALTH, 2013, 16 (03) : A163 - A163
  • [49] Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic
    Milan Kvapil
    Martin Prázný
    Pavel Holik
    Karel Rychna
    Barnaby Hunt
    Diabetes Therapy, 2017, 8 : 1331 - 1347
  • [50] Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
    Philis-Tsimikas, A.
    Del Prato, S.
    Satman, I.
    Bhargava, A.
    Dharmalingam, M.
    Skjoth, T. V.
    Rasmussen, S.
    Garber, A. J.
    DIABETES OBESITY & METABOLISM, 2013, 15 (08): : 760 - 766
12345